Biblio

Export 469 results:
Author Title [ Type(Asc)] Year
Filters: Keyword is Alzheimer Disease  [Clear All Filters]
Journal Article
J. Wang, Tan, L., and Yu, J. - T., “Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.”, J Alzheimers Dis, vol. 50, no. 4, pp. 927-45, 2016.
B. N. Dugger, Whiteside, C. M., Maarouf, C. L., Walker, D. G., Beach, T. G., Sue, L. I., Garcia, A., Dunckley, T., Meechoovet, B., Reiman, E. M., and Roher, A. E., “The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 345-56, 2016.
M. Gallucci, Spagnolo, P., Aricò, M., and Grossi, E., “Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.”, J Alzheimers Dis, vol. 50, no. 4, pp. 969-79, 2016.
A. Sinai, Mokrysz, C., Bernal, J., Bohnen, I., Bonell, S., Courtenay, K., Dodd, K., Gazizova, D., Hassiotis, A., Hillier, R., McBrien, J., McCarthy, J., Mukherji, K., Naeem, A., Perez-Achiaga, N., Rantell, K., Sharma, V., Thomas, D., Walker, Z., Whitham, S., and Strydom, A., “Predictors of Age of Diagnosis and Survival of Alzheimer's Disease in Down Syndrome.”, J Alzheimers Dis, vol. 61, no. 2, pp. 717-728, 2018.
M. Babić Leko, Borovečki, F., Dejanović, N., Hof, P. R., and Šimić, G., “Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
B. Yoon, Shim, Y. S., Park, H. - K., Park, S. Ah, Choi, S. Hye, and Yang, D. Won, “Predictive factors for disease progression in patients with early-onset Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 85-91, 2016.
L. Xu, Wu, X., Li, R., Chen, K., Long, Z., Zhang, J., Guo, X., and Yao, L., “Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1045-56, 2016.
C. Lange, Suppa, P., Pietrzyk, U., Makowski, M. R., Spies, L., Peters, O., and Buchert, R., “Prediction of Alzheimer's Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status.”, J Alzheimers Dis, vol. 61, no. 1, pp. 373-388, 2018.
Q. Tao, Zhu, H., Chen, X., Stern, R. A., Kowall, N., Au, R., Blusztajn, J. Krzysztof, and Qiu, W. Qiao, “Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 2, pp. 597-609, 2018.
G. Zhang, Zhang, Y., Shen, Y., Wang, Y., Zhao, M., and Sun, L., “The Potential Role of Ferroptosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 907-925, 2021.
G. K. Wilcock, Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., and Wischik, C. M., “Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.”, J Alzheimers Dis, vol. 61, no. 1, pp. 435-457, 2018.
S. X. Naughton, Raval, U., and Pasinetti, G. M., “Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies.”, J Alzheimers Dis, vol. 76, no. 1, pp. 21-25, 2020.
F. K. Kok, van Leerdam, S. L., and de Lange, E. C. M., “Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.”, J Alzheimers Dis, vol. 87, no. 1, pp. 51-81, 2022.
R. Smith, Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G. D., and Hansson, O., “Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.”, J Alzheimers Dis, vol. 51, no. 2, pp. 339-43, 2016.
R. E. Kennedy, Cutter, G. R., Wang, G., and Schneider, L. S., “Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1205-15, 2016.
P. L. Nara, Sindelar, D., Penn, M. S., Potempa, J., and W Griffin, S. T., “Porphyromonas gingivalis Outer Membrane Vesicles as the Major Driver of and Explanation for Neuropathogenesis, the Cholinergic Hypothesis, Iron Dyshomeostasis, and Salivary Lactoferrin in Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. 4, pp. 1417-1450, 2021.
J. Lakey-Beitia, Burillo, A. M., La Penna, G., Hegde, M. L., and Rao, K. S., “Polyphenols as Potential Metal Chelation Compounds Against Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. s1, pp. S335-S357, 2021.
B. McGuinness, Fuchs, M., Barrett, S. L., A Passmore, P., and Johnston, J. A., “Platelet Membrane β-Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal Study.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1095-103, 2016.
M. Mapstone, Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., Nazar, M. D., Rich, S. A., Berlau, D. J., Peltz, C. B., Tan, M. T., Kawas, C. H., and Federoff, H. J., “Plasma phospholipids identify antecedent memory impairment in older adults.”, Nat Med, vol. 20, no. 4, pp. 415-8, 2014.
P. Chatterjee, Lim, W. L. F., Shui, G., Gupta, V. B., James, I., Fagan, A. M., Xiong, C., Sohrabi, H. R., Taddei, K., Brown, B. M., Benzinger, T., Masters, C., Snowden, S. G., Wenk, M. R., Bateman, R. J., Morris, J. C., and Martins, R. N., “Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.”, J Alzheimers Dis, vol. 50, no. 3, pp. 887-94, 2016.
K. Deniz, Ho, C. C. G., Malphrus, K. G., Reddy, J. S., Nguyen, T., Carnwath, T. P., Crook, J. E., Lucas, J. A., Graff-Radford, N. R., Carrasquillo, M. M., and Ertekin-Taner, N., “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
M. Ettcheto, Busquets, O., Cano, A., Sánchez-López, E., Manzine, P. R., Espinosa-Jimenez, T., Verdaguer, E., Sureda, F. X., Olloquequi, J., Castro-Torres, R. D., Auladell, C., Folch, J., Casadesus, G., and Camins, A., “Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease.”, J Alzheimers Dis, vol. 82, no. s1, pp. S91-S107, 2021.
R. Milne, Bunnik, E., Diaz, A., Richard, E., Badger, S., Gove, D., Georges, J., Fauria, K., Molinuevo, J. - L., Wells, K., Ritchie, C., and Brayne, C., “Perspectives on Communicating Biomarker-Based Assessments of Alzheimer's Disease to Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 62, no. 2, pp. 487-498, 2018.
P. Suppa, Hampel, H., Kepp, T., Lange, C., Spies, L., Fiebach, J. B., Dubois, B., and Buchert, R., “Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 51, no. 3, pp. 867-73, 2016.

Pages